STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Rezolute (Nasdaq: RZLT) announced management will participate in three investor conferences in late 2025: the Maxim Growth Summit on October 22-23, 2025, the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, and the Jefferies London Healthcare Conference on November 17-20, 2025.

Management expects to hold one-on-one investor meetings during the events. Investors who want to schedule meetings are instructed to contact their Maxim, Guggenheim, or Jefferies representative.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

Event: Maxim Growth Summit
Date: October 22-23, 2025

Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 10-12, 2025

Event: Jefferies London Healthcare Conference
Date: November 17-20, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Maxim, Guggenheim, and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706


FAQ

Which investor conferences will Rezolute (RZLT) attend in Oct–Nov 2025?

Rezolute will attend the Maxim Growth Summit (Oct 22-23, 2025), Guggenheim Healthcare Innovation Conference (Nov 10-12, 2025), and Jefferies London Healthcare Conference (Nov 17-20, 2025).

How can investors schedule a meeting with Rezolute management at the Maxim Growth Summit on Oct 22-23, 2025?

Investors should contact their Maxim representative to request a one-on-one meeting with Rezolute management.

How do I arrange a one-on-one meeting with Rezolute management at the Guggenheim conference on Nov 10-12, 2025?

Schedule meetings by contacting your Guggenheim representative as indicated by Rezolute.

Who should investors contact to meet Rezolute management at the Jefferies London Healthcare Conference on Nov 17-20, 2025?

Investors should contact their Jefferies representative to arrange a meeting with Rezolute management.

Will Rezolute (RZLT) hold one-on-one investor meetings during the listed conferences?

Yes. Rezolute management will be participating in one-on-one investor meetings throughout the conferences.

What is Rezolute's Nasdaq ticker and focus mentioned in the announcement dated Oct 15, 2025?

The company trades as RZLT on Nasdaq and is described as a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism.
Rezolute Inc

NASDAQ:RZLT

RZLT Rankings

RZLT Latest News

RZLT Latest SEC Filings

RZLT Stock Data

886.48M
82.97M
9.68%
90.03%
8.53%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY